Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access

Journal of General Internal Medicine(2022)10.1007/s11606-022-07702-2Source: DataRank Database

Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access is a research paper published in Journal of General Internal Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.68)OA: bronzeTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Chelsea Sobczak ORCID,Laurel Beaty ORCID,Matthew K. Wynia ORCID,Matthew DeCamp ORCID,Vanessa Owen ORCID

Live enrichment

PubMed:35790666 PMC:PMC9255528 OpenAlex:https://openalex.org/W4284675782

National Center for Advancing Translational Sciences

Grant: 3UL1TR002535-03S3

Implementation and Real-World Effectiveness of Monoclonal Antibodies to Treat High-Risk Outpatients with COVID-19

National Center for Advancing Translational Sciences

Grant: UL1-TR002535-03

NCATS NIH HHS

Grant: UL1 TR002535

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

bronzeLicense: Springer Nature TDM

journalhttps://link.springer.com/content/pdf/10.1007/s11606-022-07702-2.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s11606-022-07702-2.pdf

publisherhttps://link.springer.com/article/10.1007/s11606-022-07702-2/fulltext.html

journalhttps://doi.org/10.1007/s11606-022-07702-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35790666

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy03 medical and health sciences0302 clinical medicineAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingHumansOutpatientsCOVID-19 Drug Treatment

MeSH Terms

COVID-19 Drug TreatmentAntibodies, MonoclonalHumansOutpatientsAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Keywords

MedicineReferralPreparednessFamily medicineCoronavirus disease 2019 (COVID-19)MEDLINEDiseaseInternal medicineInfectious disease (medical specialty)Primary CareAcute CareDiffusion Of InnovationsDissemination And ImplementationCovid-19OutpatientsAntibodies, MonoclonalHumansAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingOriginal ResearchCOVID-19 Drug Treatment

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Climate action